PERMITIL (fluphenazine hydrochloride) by Merck & Co. is clinical pharmacology fluphenazine hydrochloride has activity at all levels of the central nervous system as well as on multiple organ systems. Approved for the management of manifestations of psychotic disorders. First approved in 1965.
Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
PERMITIL (fluphenazine hydrochloride) is an oral concentrate antipsychotic approved in 1965 for managing manifestations of psychotic disorders. The mechanism of action involves activity across multiple CNS levels and organ systems, though the precise therapeutic pathway remains unknown. It represents a first-generation typical antipsychotic used primarily in chronic psychotic conditions.
As LOE approaches, the commercial team is likely in portfolio optimization mode with minimal growth investments; career mobility toward newer assets may accelerate.
CLINICAL PHARMACOLOGY Fluphenazine hydrochloride has activity at all levels of the central nervous system as well as on multiple organ systems. The mechanism whereby its therapeutic action is exerted is unknown.
Working on PERMITIL offers limited career acceleration; the zero linked job postings and LOE lifecycle indicate this is a maintenance franchise with shrinking headcount. Career professionals should evaluate this role as a stabilizing assignment or transitional step before moving to growth-stage assets within Merck's portfolio.
Worked on PERMITIL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo